NasdaqGM - Delayed Quote
USD
Protagonist Therapeutics, Inc. (PTGX)
145.72
-3.08
(-2.07%)
At close: September 4 at 4:00:00 PM EDT
145.00
-0.72
(-0.49%)
After hours: September 4 at 7:30:03 PM EDT
Trade PTGX on Coinbase
Trading disclosure
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for certain activity generated through this link. Prices displayed are informational.
Learn moreLoading chart for PTGX
- Previous Close
148.80 - Open
146.47 - Bid 97.79 x 200
- Ask 175.12 x 200
- Day's Range
144.13 - 147.99 - 52 Week Range
54.50 - 160.81 - Volume
500,996 - Avg. Volume
671,550 - Market Cap (intraday)
9.429B - Beta (5Y Monthly) 1.79
- PE Ratio (TTM)
145.72 - EPS (TTM)
1.00 - Earnings Date (est.) Nov 5, 2026
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
174.69
Recent News
View More
Performance Overview
Trailing total returns as of 9/4/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .
YTD Return
PTGX
66.84%
S&P 500 (^GSPC)
12.75%
1-Year Return
PTGX
144.50%
S&P 500 (^GSPC)
18.71%
3-Year Return
PTGX
645.75%
S&P 500 (^GSPC)
70.93%
5-Year Return
PTGX
198.12%
S&P 500 (^GSPC)
70.18%
Earnings Trends
View MoreAnalyst Insights
View MoreStatistics
View MoreValuation Measures
As of 9/3/2026
-
Market Cap
9.63B
-
Enterprise Value
8.86B
-
Trailing P/E
144.54
-
Forward P/E
36.90
-
PEG Ratio (5yr expected)
--
-
Price/Sales (ttm)
35.56
-
Price/Book (mrq)
11.45
-
Enterprise Value/Revenue
31.42
-
Enterprise Value/EBITDA
147.96
Financial Highlights
Profitability and Income Statement
-
Profit Margin
29.40%
-
Return on Assets (ttm)
4.55%
-
Return on Equity (ttm)
10.98%
-
Revenue (ttm)
281.99M
-
Net Income Avi to Common (ttm)
82.91M
-
Diluted EPS (ttm)
1.00
Balance Sheet and Cash Flow
-
Total Cash (mrq)
782.58M
-
Total Debt/Equity (mrq)
1.10%
-
Levered Free Cash Flow (ttm)
96.15M
Compare
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Mkt Cap
undefined
-
Industry
-
Mkt Cap
undefined
-
Industry
-
Company Insights
Fair Value
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Learn more
Dividend Score
The distribution of earnings a company pays back to its shareholders based off the company’s profits. Usually paid out on a quarterly basis in the form of cash or additional stocks.
Hiring Score
A company’s hiring trends in key indicators can indicate how well the company is doing in terms of growing the company and where they are currently prioritizing.
Insider Sentiment Score
Vicker’s Insider Sentiment provides insights into trades made by insiders. This can be used to gain valuable insights and as a reflection of the prospect of the company based on insider trading.
Research Reports
View More-
Lowering target price to $154.00
PROTAGONIST THERAPEUTICS INC has an Investment Rating of HOLD; a target price of $154.000000; an Industry Subrating of Medium; a Management Subrating of Medium; a Safety Subrating of High; a Financial Strength Subrating of Medium; a Growth Subrating of Medium; and a Value Subrating of High.
RatingPrice Target -
Lowering target price to $158.00
PROTAGONIST THERAPEUTICS INC has an Investment Rating of HOLD; a target price of $158.000000; an Industry Subrating of Medium; a Management Subrating of Medium; a Safety Subrating of High; a Financial Strength Subrating of Medium; a Growth Subrating of Medium; and a Value Subrating of High.
RatingPrice Target -
Raising target price to $165.00
PROTAGONIST THERAPEUTICS INC has an Investment Rating of HOLD; a target price of $165.000000; an Industry Subrating of Medium; a Management Subrating of Medium; a Safety Subrating of High; a Financial Strength Subrating of Medium; a Growth Subrating of Medium; and a Value Subrating of High.
RatingPrice Target -
Raising target price to $156.00
PROTAGONIST THERAPEUTICS INC has an Investment Rating of HOLD; a target price of $156.000000; an Industry Subrating of Medium; a Management Subrating of Medium; a Safety Subrating of High; a Financial Strength Subrating of Medium; a Growth Subrating of Medium; and a Value Subrating of High.
RatingPrice Target
